At LifeX, we help entrepreneurs develop products that have the potential to reduce suffering and mortality on a global scale
HEALTHCARE HAS TO CHANGE, BECAUSE IF WE FAIL TO ACT...
Over half of adults currently under 65 will be diagnosed with cancer1
By 2050, resistance to antibiotics will kill more people than cancer2
65 million more adults in the US will be obese by 20303
OUR MISSION TO HELP REDUCE THE GLOBAL DISEASE BURDEN
Complex illnesses are putting an unprecedented strain on healthcare systems that are already stretched. At LifeX, we believe entrepreneurs can change this.
Where others might see challenges that are just too difficult to meet, we see problems that can be solved.
THE LABS ARE OUR HOME
Exceptional start-up companies are invited to move their operations to our foundry in Pittsburgh. Here, companies can realize their vision, hone their skills and gather the momentum necessary to bring their products to the marketplace.
STORIES OF SUCCESS
Companies in the LifeX Portfolio have three things in common: they address large market needs, have innovation based on technology convergence and billion-dollar potential. Facilitated by LifeX Labs.
LifeX represents a one-of-a-kind opportunity. It’s about realizing potential and making a tangible difference to those who suffer needlessly around the world.
To that end, we have built a forward-thinking portfolio, with first-in-class solutions and the proven ability to earn significant financial returns.
The University of Pittsburgh and its Graduate School of Public Health together with the Henry L. Hillman Foundation support LifeX Labs.
1. Ahmad AS et al. Brit J Cancer 2015; 112: 943–947. 2.The Review on Antimicrobial Resistance 2016 https://amr-review.org Accessed April 2018. 3. 'Half of UK obese by 2030' https://www.nhs.uk/news/obesity/half-of-uk-obese-by-2030/ Accessed April 2018.